Want to see SE:APOTEA full AI Analyst Report?
APOTEA Stock Chart & Stats
kr66.50
-kr0.22(-0.29%)
At close: 4:00 PM EST
kr66.50
-kr0.22(-0.29%)
Day’s Range― - ―
52-Week Rangekr54.42 - kr122.00
Previous CloseN/A
Volume107.34K
Average Volume (3M)136.78K
Market Cap
kr7.67B
Enterprise Valuekr6.77K
Total Cash (Recent Filing)kr103.50M
Total Debt (Recent Filing)kr279.30M
Price to Earnings (P/E)35.0
Beta0.44
Next Earnings
Nov 05, 2026EPS Estimate
0.71Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.36
Shares Outstanding104,070,970
10 Day Avg. Volume129,131
30 Day Avg. Volume136,777
Financial Highlights & Ratios
PEG Ratio7.96
Price to Book (P/B)11.37
Price to Sales (P/S)1.33
P/FCF Ratio81.54
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)2.71
Revenue Forecast (FY)kr8.07B
Bulls Say, Bears Say
Bulls Say
Pure-play Online Pharmacy ModelA dedicated online pharmacy and health e-commerce model aligns revenue to recurring consumer demand and prescription flows. Direct-to-consumer distribution enables unit-cost advantages via scale, automated fulfilment and logistics efficiencies, supporting durable margin improvements as volume grows.
Sustained Revenue Growth And Improving ProfitContinued top-line expansion alongside steady operating and net profitability signals the business is converting scale into lasting earnings power. Stable gross margins and improved operating results versus prior weak years indicate structural progress in cost control and assortment/mix management.
Manageable Leverage And Growing Equity BaseA capital structure with debt around one-third of equity and improving leverage ratios provides financial flexibility for reinvestment or absorption of shocks. Growing equity alongside assets supports balance-sheet resilience and reduces near-term refinancing pressure compared with higher-levered peers.
Bears Say
Weak And Volatile Free Cash FlowSharp FCF decline and historically volatile cash conversion weaken internal funding for growth, capex, or dividends. Reliance on external financing or equity issuance could rise during slower periods, constraining long-term investment and increasing sensitivity to funding cost changes.
Thin Profit MarginsModest operating and net margins leave limited buffer against cost inflation, pricing pressure, or reimbursement shifts. With profitability near single digits, the company is more exposed to demand swings and competitive discounting, which can erode sustainable cash generation over months to years.
Volatile Earnings GrowthSevere negative EPS growth indicates earnings volatility and potential one-off impacts in recent periods. Persistent EPS swings can undermine investor confidence, raise cost of capital, and signal underlying operational inconsistency that may constrain long-term strategic planning and reinvestment.
Apotea AB News
APOTEA FAQ
What was Apotea AB’s price range in the past 12 months?
Apotea AB lowest stock price was kr54.42 and its highest was kr122.00 in the past 12 months.
What is Apotea AB’s market cap?
Apotea AB’s market cap is kr7.67B.
When is Apotea AB’s upcoming earnings report date?
Apotea AB’s upcoming earnings report date is Nov 05, 2026 which is in 110 days.
How were Apotea AB’s earnings last quarter?
Apotea AB released its earnings results on Jul 17, 2026. The company reported kr0.8 earnings per share for the quarter, beating the consensus estimate of kr0.71 by kr0.09.
Is Apotea AB overvalued?
According to Wall Street analysts Apotea AB’s price is currently Overvalued.
Does Apotea AB pay dividends?
Apotea AB pays a N/A dividend of kr0.6 which represents an annual dividend yield of N/A. See more information on Apotea AB dividends here
What is Apotea AB’s EPS estimate?
Apotea AB’s EPS estimate is 0.71.
How many shares outstanding does Apotea AB have?
Apotea AB has 104,070,970 shares outstanding.
What happened to Apotea AB’s price movement after its last earnings report?
Apotea AB reported an EPS of kr0.8 in its last earnings report, beating expectations of kr0.71. Following the earnings report the stock price went up 7.87%.
Which hedge fund is a major shareholder of Apotea AB?
Currently, no hedge funds are holding shares in SE:APOTEA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Apotea AB
Apotea AB (publ) operates an online pharmacy in Sweden. The company offers products in the areas of allergy, face, child and parent, bite and sting, preparedness, animal, fever and aches, cold, home and household, aid, hair removal and shaving, hair care, hands and feet, intimate, and dietary supplements. It also provides products in the categories of body care, stomach and intestine, food and drink, mouth and teeth, premium, trip, sex and lust, stop smoking, makeup, sun protection, wounds and injuries, sleep and sleep problems, training, weight control, vitamins and minerals, charity, and eyes and ears. In addition, the company offers services comprising leasing, leasing of personnel to related companies. and market contributions. The company was founded in 2011 and is headquartered in Stockholm, Sweden.